{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:51:36Z","timestamp":1788317496994,"version":"build-2803163510"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>3,4-Methylenedioxymethamphetamine (MDMA, or ecstasy) is a recreational drug being investigated for the treatment of posttraumatic stress disorder. Acute hyponatremia is a potentially serious complication after even a single dose of MDMA. The assumed etiology has been a vasopressin release inducing the syndrome of inappropriate antidiuresis combined with increased thirst, causing polydipsia and water intoxication.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the incidence and severity of hyponatremia after a single dose of MDMA, underlying neuroendocrine mechanisms of action, and the potential effect of fluid restriction on lowering the incidence of hyponatremia.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This ad hoc secondary analysis pooled data from 4 placebo-controlled crossover randomized clinical trials conducted at the University Hospital Basel, Basel, Switzerland. The 96 participants received experimental doses of MDMA between March 1, 2017, and August 31, 2022.<\/jats:p><\/jats:sec>Intervention<\/jats:title>A single oral 100- or 125-mg dose of MDMA. Fluid intake was not restricted in 81 participants; it was restricted in 15.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Plasma oxytocin, copeptin (marker of vasopressin), and sodium levels were measured repeatedly within 360 minutes after MDMA intake. The association of plasma oxytocin or copeptin levels with plasma sodium level at 180 minutes (peak concentration of MDMA) was determined.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 96 participants, the mean (SD) age was 29 (7) years, and 62 (65%) were men. A total of 39 participants (41%) received a 100-mg dose of MDMA, and 57 (59%) received a 125-mg dose. At baseline, the mean (SD) plasma sodium level was 140 (3) mEq\/L and decreased in response to MDMA by 3 (3) mEq\/L. Hyponatremia occurred in 30 participants (31%) with a mean (SD) sodium level of 133 (2) mEq\/L. In 15 participants with restricted fluid intake, no hyponatremia occurred, while in the 81 participants with unrestricted fluid intake, hyponatremia occurred in 30 (37%) (P<\/jats:italic>\u2009=\u2009.002) with a difference in plasma sodium of 4 (95% CI, 2-5) mEq\/L (P<\/jats:italic>\u2009&amp;lt;\u2009.001) between both groups, suggesting that fluid restriction may mitigate the risk of hyponatremia. At baseline, the mean (SD) plasma oxytocin level was 87 (45) pg\/mL and increased in response to MDMA by 388 (297) pg\/mL (ie, a mean [SD] 433% [431%] increase at 180 minutes), while the mean (SD) copeptin level was 4.9 (3.8) pmol\/L and slightly decreased, by 0.8 (3.0) pmol\/L. Change in plasma sodium level from baseline to 180 minutes demonstrated a negative correlation with the changes in oxytocin (R<\/jats:italic>\u2009=\u2009\u22120.4; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and MDMA (R<\/jats:italic>\u2009=\u2009\u22120.4; P<\/jats:italic>\u2009&amp;lt;\u2009.001) levels while showing no correlation with the change in copeptin level.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this secondary analysis of 4 randomized clinical trials, a high incidence of acute hyponatremia was observed in response to MDMA, which may be mitigated by fluid restriction. Hyponatremia was associated with acute oxytocin but not copeptin release. This challenges the current hypothesis of direct vasopressin release and rather indicates that oxytocin mimics the effect of vasopressin in the kidneys due to structural homology.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.45278","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:31:30Z","timestamp":1731688290000},"page":"e2445278","source":"Crossref","is-referenced-by-count":15,"title":["Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia"],"prefix":"10.1001","volume":"7","author":[{"given":"Cihan","family":"Atila","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Straumann","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland"},{"name":"Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vizeli","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland"},{"name":"Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Monnerat","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Holze","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland"},{"name":"Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland"},{"name":"Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Christ-Crain","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland"},{"name":"Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"issue":"6","key":"zoi241290r1","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"zoi241290r2","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2215\/CJN.02080508","article-title":"The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney.","volume":"3","author":"Campbell","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"zoi241290r3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.akdh.2022.11.004","article-title":"Hyponatremia demystified: integrating physiology to shape clinical practice.","volume":"30","author":"Workeneh","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"3","key":"zoi241290r4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bjp.0704502","article-title":"The effect of 3,4-methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus.","volume":"135","author":"Forsling","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"16","key":"zoi241290r5","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/NEJMcp2210411","article-title":"The syndrome of inappropriate antidiuresis.","volume":"389","author":"Adrogu\u00e9","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi241290r6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","article-title":"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.","volume":"45","author":"Holze","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"zoi241290r7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.906639","article-title":"Effects of 3,4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects.","volume":"13","author":"Vizeli","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"zoi241290r8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2213-8587(23)00120-1","article-title":"Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial.","volume":"11","author":"Atila","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"zoi241290r9","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41386-023-01609-0","article-title":"Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.","volume":"48","author":"Straumann","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"zoi241290r10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"zoi241290r12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0269881108100020","article-title":"Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology.","volume":"24","author":"Dumont","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"11","key":"zoi241290r13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.7326\/0003-4819-117-11-891","article-title":"Postoperative hyponatremic encephalopathy in menstruant women.","volume":"117","author":"Ayus","year":"1992","journal-title":"Ann Intern Med"},{"issue":"6916","key":"zoi241290r14","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/bmj.307.6916.1399","article-title":"Hyponatraemia and catatonic stupor after taking \u201cecstasy.\u201d","volume":"307","author":"Maxwell","year":"1993","journal-title":"BMJ"},{"key":"zoi241290r15","doi-asserted-by":"publisher","journal-title":"Cureus","DOI":"10.7759\/cureus.15223"},{"key":"zoi241290r16","doi-asserted-by":"publisher","journal-title":"Am J Med Sci","DOI":"10.1097\/00000441-200308000-00006"},{"key":"zoi241290r17","doi-asserted-by":"publisher","journal-title":"J Emerg Med","DOI":"10.1016\/j.jemermed.2009.05.001"},{"issue":"9","key":"zoi241290r18","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1210\/jc.2011-1143","article-title":"Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects.","volume":"96","author":"Simmler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9118","key":"zoi241290r19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/S0140-6736(05)78744-4","article-title":"Low-dose MDMA (\u201cecstasy\u201d) induces vasopressin secretion.","volume":"351","author":"Henry","year":"1998","journal-title":"Lancet"},{"key":"zoi241290r20","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2175896","article-title":"MDMA impairs response to water intake in healthy volunteers.","volume":"2016","author":"Baggott","year":"2016","journal-title":"Adv Pharmacol Sci"},{"key":"zoi241290r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2006.09.018","author":"Rosenson","year":"2007","journal-title":"Ann Emerg Med"},{"issue":"9","key":"zoi241290r22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/ndt\/gft192","article-title":"Ecstacy-associated hyponatremia: why are women at risk?","volume":"28","author":"Moritz","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"zoi241290r23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.taap.2009.09.008","article-title":"Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).","volume":"241","author":"Fonsart","year":"2009","journal-title":"Toxicol Appl Pharmacol"},{"issue":"9","key":"zoi241290r24","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/ndt\/gft023","article-title":"High incidence of mild hyponatraemia in females using ecstasy at a rave party.","volume":"28","author":"van Dijken","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"zoi241290r25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1211\/0022357011777855","article-title":"Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): is metabolism a contributory factor?","volume":"53","author":"Forsling","year":"2001","journal-title":"J Pharm Pharmacol"},{"issue":"9007","key":"zoi241290r26","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/S0140-6736(96)90196-8","article-title":"Near-fatal hyponatraemic coma due to vasopressin over-secretion after \u201cecstasy\u201d (3,4-MDMA).","volume":"347","author":"Holden","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"zoi241290r27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/0269881106061514","article-title":"Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population.","volume":"20","author":"Wolff","year":"2006","journal-title":"J Psychopharmacol"},{"key":"zoi241290r28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1749-6632.2002.tb04181.x","article-title":"Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release.","volume":"965","author":"Fallon","year":"2002","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"zoi241290r29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neuroscience.2007.02.032","article-title":"A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (\u201cecstasy\u201d).","volume":"146","author":"Thompson","year":"2007","journal-title":"Neuroscience"},{"key":"zoi241290r30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psyneuen.2014.04.006","article-title":"Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans.","volume":"46","author":"Kirkpatrick","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"zoi241290r31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.neubiorev.2015.08.016","article-title":"The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals.","volume":"57","author":"Kamilar-Britt","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"zoi241290r32","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.pnpbp.2005.04.009","article-title":"Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.","volume":"29","author":"Morley","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"zoi241290r33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1055\/s-0032-1306296","article-title":"Hyponatraemia and brain oedema in newborns following oral water intoxication during prolonged labour.","volume":"224","author":"Walter","year":"2012","journal-title":"Klin Padiatr"},{"issue":"1","key":"zoi241290r34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/0002-9378(75)90965-5","article-title":"Water intoxication associated with oxytocin administration during saline-induced abortion.","volume":"121","author":"Lauersen","year":"1975","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"zoi241290r35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1471-0528.2008.02063.x","article-title":"Hyponatremia complicating labour\u2014rare or unrecognised? a prospective observational study.","volume":"116","author":"Moen","year":"2009","journal-title":"BJOG"},{"issue":"10","key":"zoi241290r36","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1093\/ndt\/gfh413","article-title":"Antidiuretic action of oxytocin is associated with increased urinary excretion of aquaporin-2.","volume":"19","author":"Joo","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"3, pt 2","key":"zoi241290r37","doi-asserted-by":"publisher","first-page":"R444","DOI":"10.1152\/ajpregu.1986.250.3.R444","article-title":"Osmotic regulation of plasma vasopressin and oxytocin after sustained hyponatremia.","volume":"250","author":"Verbalis","year":"1986","journal-title":"Am J Physiol"},{"key":"zoi241290r38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yfrne.2017.10.004","article-title":"Cross-talk among oxytocin and arginine-vasopressin receptors: relevance for basic and clinical studies of the brain and periphery.","volume":"51","author":"Song","year":"2018","journal-title":"Front Neuroendocrinol"},{"key":"zoi241290r39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fnins.2015.00335","article-title":"Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits.","volume":"9","author":"Baribeau","year":"2015","journal-title":"Front Neurosci"},{"issue":"2","key":"zoi241290r40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1152\/physrev.2001.81.2.629","article-title":"The oxytocin receptor system: structure, function, and regulation.","volume":"81","author":"Gimpl","year":"2001","journal-title":"Physiol Rev"},{"key":"zoi241290r41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0079-6123(08)00437-8","article-title":"Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.","volume":"170","author":"Manning","year":"2008","journal-title":"Prog Brain Res"},{"issue":"5-6","key":"zoi241290r42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/FBP.0000000000000060","article-title":"MDMA, cortisol, and heightened stress in recreational ecstasy users.","volume":"25","author":"Parrott","year":"2014","journal-title":"Behav Pharmacol"},{"issue":"1","key":"zoi241290r43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/0269881112454231","article-title":"MDMA can increase cortisol levels by 800% in dance clubbers.","volume":"27","author":"Parrott","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"5","key":"zoi241290r44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/00063110-200410000-00014","article-title":"Polydipsia as another mechanism of hyponatremia after \u201cecstasy\u201d (3,4 methyldioxymethamphetamine) ingestion.","volume":"11","author":"Brvar","year":"2004","journal-title":"Eur J Emerg Med"},{"key":"zoi241290r11","unstructured":"European Commission. Guidelines: the rules governing medicinal products in the European Union volume 4 EU guidelines for good manufacturing practice for medicinal products for human and veterinary use. August 22, 2022. Accessed October 15, 2024. https:\/\/www.gmp-compliance.org\/files\/guidemgr\/20220825_gmp-an1_en_0.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2826211\/atila_2024_oi_241290_1730997031.50508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:31:33Z","timestamp":1731688293000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2826211"}},"subtitle":["A Secondary Analysis of 4 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.45278","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}